Publicacións en colaboración con investigadores/as de Universidad de Castilla-La Mancha (10)

2023

  1. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

    Frontiers in Public Health, Vol. 11

2022

  1. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953

  2. The economic burden of pulmonary arterial hypertension in Spain

    BMC Pulmonary Medicine, Vol. 22, Núm. 1

  3. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

    Acta Dermato-Venereologica, Vol. 102

2021

  1. A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin

    Drug Delivery and Translational Research, Vol. 11, Núm. 2, pp. 524-545

  2. Correction to: A nanoemulsion/micelles mixed nanosystem for the oral administration of hydrophobically modified insulin (Drug Delivery and Translational Research, (2021), 11, 2, (524-545), 10.1007/s13346-021-00920-x)

    Drug Delivery and Translational Research

2020

  1. In vitro relevant information for the assessment of nanoparticles for oral drug administration

    Nanotechnology for Oral Drug Delivery: From Concept to Applications (Elsevier), pp. 419-458

2018

  1. Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis

    BioDrugs, Vol. 32, Núm. 3, pp. 281-291

  2. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Journal of Controlled Release, Vol. 276, pp. 125-139

2016

  1. Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size

    International Journal of Pharmaceutics, Vol. 509, Núm. 1-2, pp. 107-117